BioNTech SE stock faces a lower target after guidance cut

Published on 09/22/2026 at 14:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BioNTech SE stock faces a BMO target cut from USD 128 to USD 105 on September 8, 2026. Q1 revenue was EUR 118.1 million.

BioNTech SE, US09075V1026, Illustration mit AI erstellt.

BioNTech SE stock (ISIN US09075V1026) closed at EUR 85.00 in Frankfurt on September 21, 2026, up 0.24 percent from EUR 84.80. The valuation was accompanied by a reduced revenue outlook and a lower analyst price target.

Guidance cut weighs on valuation

According to The Motley Fool on September 22, 2026, BMO Capital Markets downgraded BioNTech from outperform to market perform on September 8, 2026 and cut its 12-month price target from USD 128 to USD 105.

The same report said BioNTech reduced its full-year 2026 revenue guidance on August 28, 2026, from EUR 2.0 billion to EUR 2.3 billion previously to EUR 1.6 billion to EUR 1.9 billion. The lower range represents a reduction of EUR 400 million at the lower end and EUR 400 million at the upper end.

Pipeline remains the counterweight

The latest quarterly market data show Q1 FY2026 revenue of EUR 118.1 million and earnings of negative EUR 531.9 million, with a reported profit margin of negative 450.38 percent. These figures provide a difficult earnings backdrop while the company invests in oncology programs.

BioNTech's development pipeline still contains more than 25 oncology candidates in Phase 2 and Phase 3 trials, according to The Motley Fool on September 22, 2026. The report also noted that gotistobart nearly doubled median overall survival versus standard chemotherapy in previously treated patients with squamous non-small cell lung cancer.

That pipeline is the central counterweight to the guidance reduction. The immediate financial comparison is negative, but the clinical portfolio gives the stock a second valuation driver beyond declining COVID-19 vaccine demand.

Stock trades below yearly high

Yahoo Finance data showed BioNTech at EUR 85.00 on September 21, 2026, within a 52-week range of EUR 68.00 to EUR 105.50. The closing price was EUR 20.50 below the reported yearly high, while market capitalization stood at EUR 21.352 billion and volume at 526 shares.

For investors, the figures point to a company valued on future oncology execution while current earnings remain pressured. The next reported earnings date shown in the market data is November 3, 2026.

BioNTech stock closes at EUR 85

BioNTech stock closed at EUR 85.00 on the Frankfurt market on September 21, 2026, with a daily gain of 0.24 percent. The price remained EUR 20.50 below the 52-week high of EUR 105.50.